Jazz Pharmaceuticals Future Growth
Future criteria checks 2/6
Jazz Pharmaceuticals is forecast to grow earnings and revenue by 16.3% and 5.6% per annum respectively. EPS is expected to grow by 16.2% per annum. Return on equity is forecast to be 15.1% in 3 years.
Key information
16.3%
Earnings growth rate
16.2%
EPS growth rate
Pharmaceuticals earnings growth | 23.9% |
Revenue growth rate | 5.6% |
Future return on equity | 15.1% |
Analyst coverage | Good |
Last updated | 17 Dec 2024 |
Recent future growth updates
Recent updates
Jazz Pharmaceuticals: High Uncertainty, Low Risk
Nov 18We Think Jazz Pharmaceuticals' (NASDAQ:JAZZ) Profit Is Only A Baseline For What They Can Achieve
Nov 14Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?
Oct 22Jazz Pharmaceuticals: Unexpected Wins Improve The Long-Term Outlook
Oct 16Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Looks Inexpensive But Perhaps Not Attractive Enough
Sep 25Jazz Pharmaceuticals: Zanidatamab Is A Potential Growth Catalyst
Sep 19Here's Why Shareholders Should Examine Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) CEO Compensation Package More Closely
Jul 18Here's Why Jazz Pharmaceuticals (NASDAQ:JAZZ) Has A Meaningful Debt Burden
Jun 23Jazz Pharmaceuticals: Pipeline Setback While Business Transition Continues
Jun 21Jazz Pharmaceuticals: Targeting The Low-Hanging Fruit In Oncology Might Pay Off
Apr 15Insufficient Growth At Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Hampers Share Price
Apr 02Is Jazz Pharmaceuticals (NASDAQ:JAZZ) A Risky Investment?
Feb 18Updated View On Jazz Pharmaceuticals' 2025 Goals
Jan 29Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Price Is Right But Growth Is Lacking
Dec 26Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 4,501 | 645 | 1,694 | 1,428 | 18 |
12/31/2025 | 4,324 | 590 | 1,497 | 1,497 | 19 |
12/31/2024 | 4,039 | 515 | 1,168 | 1,362 | 19 |
9/30/2024 | 3,993 | 463 | 1,102 | 1,165 | N/A |
6/30/2024 | 3,910 | 395 | 1,017 | 1,073 | N/A |
3/31/2024 | 3,843 | 331 | 983 | 1,039 | N/A |
12/31/2023 | 3,834 | 415 | 1,049 | 1,092 | N/A |
9/30/2023 | 3,794 | 80 | 867 | 1,267 | N/A |
6/30/2023 | 3,763 | -87 | 987 | 1,377 | N/A |
3/31/2023 | 3,738 | -156 | 918 | 1,384 | N/A |
12/31/2022 | 3,659 | -224 | 774 | 1,272 | N/A |
9/30/2022 | 3,584 | -19 | 984 | 1,108 | N/A |
6/30/2022 | 3,481 | -52 | 809 | 964 | N/A |
3/31/2022 | 3,300 | -450 | 622 | 702 | N/A |
12/31/2021 | 3,094 | -330 | 733 | 779 | N/A |
9/30/2021 | 2,863 | -161 | 711 | 787 | N/A |
6/30/2021 | 2,626 | 40 | 708 | 771 | N/A |
3/31/2021 | 2,436 | 518 | 750 | 912 | N/A |
12/31/2020 | 2,364 | 239 | 520 | 900 | N/A |
9/30/2020 | 2,280 | 179 | 455 | 801 | N/A |
6/30/2020 | 2,217 | 133 | 478 | 881 | N/A |
3/31/2020 | 2,188 | 280 | 509 | 847 | N/A |
12/31/2019 | 2,162 | 523 | 594 | 776 | N/A |
9/30/2019 | 2,056 | 609 | 726 | 907 | N/A |
6/30/2019 | 1,988 | 656 | 676 | 791 | N/A |
3/31/2019 | 1,954 | 486 | 646 | 834 | N/A |
12/31/2018 | 1,891 | 447 | 667 | 799 | N/A |
9/30/2018 | 1,851 | 520 | 642 | 785 | N/A |
6/30/2018 | 1,793 | 434 | N/A | 753 | N/A |
3/31/2018 | 1,687 | 447 | N/A | 696 | N/A |
12/31/2017 | 1,619 | 488 | N/A | 693 | N/A |
9/30/2017 | 1,579 | 372 | N/A | 669 | N/A |
6/30/2017 | 1,541 | 399 | N/A | 613 | N/A |
3/31/2017 | 1,528 | 408 | N/A | 605 | N/A |
12/31/2016 | 1,488 | 397 | N/A | 592 | N/A |
9/30/2016 | 1,432 | 363 | N/A | 531 | N/A |
6/30/2016 | 1,399 | 361 | N/A | 573 | N/A |
3/31/2016 | 1,352 | 335 | N/A | 587 | N/A |
12/31/2015 | 1,325 | 330 | N/A | 532 | N/A |
9/30/2015 | 1,312 | 328 | N/A | 545 | N/A |
6/30/2015 | 1,278 | 266 | N/A | 499 | N/A |
3/31/2015 | 1,235 | 222 | N/A | 434 | N/A |
12/31/2014 | 1,173 | 58 | N/A | 408 | N/A |
9/30/2014 | 1,081 | 32 | N/A | 353 | N/A |
6/30/2014 | 1,006 | 82 | N/A | 354 | N/A |
3/31/2014 | 923 | 80 | N/A | 287 | N/A |
12/31/2013 | 872 | 216 | N/A | 288 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: JAZZ's forecast earnings growth (16.3% per year) is above the savings rate (2.6%).
Earnings vs Market: JAZZ's earnings (16.3% per year) are forecast to grow faster than the US market (15.2% per year).
High Growth Earnings: JAZZ's earnings are forecast to grow, but not significantly.
Revenue vs Market: JAZZ's revenue (5.6% per year) is forecast to grow slower than the US market (9.1% per year).
High Growth Revenue: JAZZ's revenue (5.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: JAZZ's Return on Equity is forecast to be low in 3 years time (15.1%).
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/22 02:34 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Jazz Pharmaceuticals plc is covered by 51 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Joel Beatty | Baird |
Ishan Majumdar | Baptista Research |
Richard Silver | Barclays |